Assessing cognitive trajectories in Progressive Supranuclear Palsy using remote computerized reaction time tasks (Trial Not Registered)

This study aims to assess the potential role for remote computerised cognitive battery measurements in detecting short-term cognitive decline in PSP, and to explore its role as a novel biomarker for disease progression in descriptive and therapeutic clinical trials.

Trial phase

Other

Trial participation type

This trial has been designed for the Clinical Research of a Device.

Principal investigator

Dr Kelly Bertram

Key inclusion data

Inclusion: Participants aged 40 or over with a diagnosis of PSP according to the 2017 MDS criteria made by a Neurologist; Registered study participant of the Alfred Neurology BioData bank (Alfred HREC 157/19) and consenting to data and material sharing; Current right of access to Medicare as per Commonwealth and Victorian State government policy. Exclusion: Significant neurological or neuropsychiatric diagnosis deemed to interfere with cognitive or other testing (e.g., Alzheimers disease, schizophrenia etc); Unable to complete study protocol procedures (e.g., severely disabling disease, non-English speaking, geographical location, no access to suitable device for CCB completion, no access to internet connection).